Brian Druker, MD and Tony Hunter PhD

Tony Hunter, PhD, and Brian Druker ’77, MD ’81, contributed to the development of Gleevec, the first cancer drug to target cell growth without harming healthy cells.

Hunter’s research into the mechanisms of cancer cell growth laid the foundation for Druker’s work targeting enzymes to treat chronic myeloid leukemia.

Today, Hunter investigates protein mediated cell growth, uncovering new chemical pathways that control cancer behavior. Druker explores ways to improve early cancer detection and increase cancer survival rates using precision medicine techniques.